Alzheimer preclinical model for the evaluation of
cognitive-enhancing drugs: Memantine validation

Newsletter # 65

Animal models


The NMDA-receptor antagonist Memantine is a FDA-approved drug used to treat Alzheimer-type dementia, especially for patients who have a contraindication to acetylcholinesterase inhibitors. Although clinical evidences support the cognitive-enhancing effect of memantine, the effect in rodents is not very clear yet and results reported so far are not always consistent.

Here we provide a clear-cut result that validate the cognitive enhancing effect of memantine in a rodent model of Alzheimer's disease.

  • Memantine reverses β-amyloid-induced cognitive deficits




  • ■ In this Rat model, cognitive deficit is induced by Intracerebroventricular injection of β-amyloid.

    ■ Treatment with Memantine fully reverses the cognitive deficit.

    ■ This model provides a robust preclinical assay for evaluation of cognitive-enhancing drugs, especially in Alzheimer-type dementia.


NEUROFIT offers a range of validated in vitro and in vivo screening tests for psychiatry and neurology.

If you need further information, please do not hesitate to contact us, we will reply within few days. Custom protocol

On a regular basis we distribute newsletters with scientific information on our research services. If you wish to receive these, please :